Clinical trial DALY 2-EU
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation (M-2020-371)
Cancers | |
---|---|
Organ | Non-Hodgkin lymphoma |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | Miltenyi Biomedicine GmbH |
EudraCT Identifier | 2020-003908-14 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04844866 |
Inclusion criteria | - Histologically proven DLBCL and associated subtypes- Relapsed or refractory disease after first-line chemoimmunotherapy- Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regime |
Last update |